In the Claims

Please amend the claims as follows:

Please amend claim 104 as indicated below.

Please cancel claim 116 without prejudice or disclaimer.

- 1-103. (canceled)
- 104. (currently amended) A method for treating a subject having a tumor, comprising: administering to a vertebrate subject having a tumor a tumor-specific antigen and an oligonucleotide 10-50 nucleotides long comprising a sequence chosen from GGGGG, GAGGG, GGGAG, GTGGG, and GGGTG, wherein the oligonucleotide does not comprise a CG dinucleotide, in order to treat the subject.
- 105. (previously presented) The method of claim 104, wherein the oligonucleotide is DNA.
- 106. (previously presented) The method of claim 104, wherein the oligonucleotide is RNA.
- 107. (previously presented) The method of claim 104, wherein at least one nucleotide of the oligonucleotide is replaced by a corresponding nucleotide analog or derivative.
- 108. (previously presented) The method of claim 104, wherein at least one nucleotide of the sequence is replaced by a corresponding nucleotide analog or derivative.
- 109. (previously presented) The method of claim 104, wherein at least two nucleotides of the oligonucleotide are linked by a nuclease-resistant bond.
- 110. (previously presented) The method of claim 109, wherein the nuclease-resistant bond is selected from the group consisting of phosphorothioate, methylphosphonate, and peptide bonds.

- 111. (canceled)
- 112. (previously presented) The method of claim 104, wherein the oligonucleotide is 13-30 nucleotides long.
- 113. (previously presented) The method of claim 104, wherein the oligonucleotide is 17-21 nucleotides long.
- 114. (previously presented) The method of claim 104, wherein the sequence represents the 3' terminus of the oligonucleotide.
- 115-171. (canceled)